Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy

Intouch Sakpakdeejaroen, Sukrut Somani, Margaret Mullin, Christine Dufès

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors.

In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.
Original languageEnglish
Number of pages30
JournalJournal of Liposome Research
Publication statusAccepted/In press - 22 Apr 2019

Keywords

  • aspirin
  • transferrin
  • tumor targeting
  • drug delivery
  • cancer therapy

Cite this